Fluorescent HTS Assay for Histidine-Tagged Proteins

Information

  • Research Project
  • 6335998
  • ApplicationId
    6335998
  • Core Project Number
    R43GM062035
  • Full Project Number
    1R43GM062035-01A1
  • Serial Number
    62035
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/2001 - 23 years ago
  • Project End Date
    10/31/2002 - 22 years ago
  • Program Officer Name
    OKITA, RICHARD T.
  • Budget Start Date
    6/1/2001 - 23 years ago
  • Budget End Date
    10/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    6/1/2001 - 23 years ago
Organizations

Fluorescent HTS Assay for Histidine-Tagged Proteins

DESCRIPTION (provided by applicant): The recent outpouring of human genome sequence and gene expression data has fundamentally changed drug discovery. The rate at which new molecular targets are being identified is increasing rapidly, and the ability to provide purified recombinant human proteins for high throughput screening will soon become a bottleneck in the identification of lead molecules. A key technical hurdle is the capability to rapidly screen multiple expression parameters to identify conditions for expression of properly folded human proteins in E. coli and baculovirus infected insect cells. Achieving this will require methods for rapidly quantifying the expression level of recombinant proteins in crude cell extracts. Accordingly, PanVera has undertaken development of a novel fluorescent method for quantifying affinity-tagged proteins; the extensively used polyhistidine motif (HisTag) will serve as a model system in Phase I. With the developments included in this Phase I proposal, this assay method will enable rapid and sensitive quantification of the absolute levels of any protein with a HisTag using a simple mix-and-read, multiwell format. The availability of such homogenous assays for quantification of diverse proteins will enhance the capabilities of individual investigators trying to isolate novel proteins and will accelerate industrial efforts to multiplex and automate protein expression methods. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    150331
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:150331\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PANVERA CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    MADISON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    53711
  • Organization District
    UNITED STATES